NeuroBo Pharmaceuticals (NASDAQ:NRBO) Stock Price Up 6.8%

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBOGet Free Report)’s share price traded up 6.8% during trading on Thursday . The stock traded as high as $4.25 and last traded at $4.10. 81,193 shares were traded during trading, a decline of 89% from the average session volume of 726,369 shares. The stock had previously closed at $3.84.

Analyst Upgrades and Downgrades

Separately, Maxim Group assumed coverage on shares of NeuroBo Pharmaceuticals in a research report on Wednesday, May 8th. They set a “buy” rating and a $10.00 price objective for the company.

View Our Latest Stock Analysis on NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals Price Performance

The stock’s 50-day moving average is $3.84 and its 200 day moving average is $4.10.

NeuroBo Pharmaceuticals (NASDAQ:NRBOGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.37). Equities analysts forecast that NeuroBo Pharmaceuticals, Inc. will post -4.89 EPS for the current year.

About NeuroBo Pharmaceuticals

(Get Free Report)

NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity.

Featured Stories

Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.